Immunotherapy and Chemotherapy Shrink Peritoneal Mesothelioma Tumors: New Case Reports
Two new case reports appear to support the idea that immunotherapy and chemotherapy can work together to fight peritoneal mesothelioma. …
Relapsed Mesothelioma Patients Live Longer on Opdivo in Phase 3 Trial
A multi-center British study suggests that the cancer drug Opdivo (nivolumab) may be a solid second-line treatment option for relapsed…
Immune Checkpoint Inhibitors for Recurrent Mesothelioma: Early Adoption Gave Them Traction
A new report shows that doctors started using immune checkpoint inhibitors for recurrent mesothelioma at least two years before the…
Statin Drugs Support Immunotherapy for Mesothelioma, New Study Finds
There’s more evidence that statin drugs may improve the effectiveness of mesothelioma immunotherapy. The new study, led by Korean biochemists,…
Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good
Three years after the last patients enrolled in the clinical trial of Yervoy and Opdivo for mesothelioma, survival results still…
Immune Checkpoint Inhibitor Safe Both Before and After Mesothelioma Surgery
A report presented to an international gathering of lung cancer doctors shows an immune checkpoint inhibitor can make pre-surgery chemotherapy…
Mesothelioma Update: Could New Form of Immunotherapy Help?
A new form of immunotherapy using a patient’s own cells is making headlines this month after a new study shows…
New “Real World” Study of Immunotherapy for Peritoneal Mesothelioma
A new study from one of the nation’s top cancer centers supports the role of immunotherapy in peritoneal mesothelioma treatment.…
Comparing Second-Line Therapies for Recurrent Mesothelioma
University of Pennsylvania researchers have some hopeful news for people with recurrent mesothelioma after chemotherapy: Second-line immunotherapy might increase their…
New PD-L1 Inhibitor Could Make Mesothelioma Immunotherapy Safer
A new PD-L1 inhibitor may be on the horizon for people with malignant mesothelioma. A Phase I trial suggests it…